Loading news...
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) has been given a consensus recommendation of "Buy" by the twenty-two brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, nineteen have issued a buy recommendation and two have assigned a strong buy recommendation to the
Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.
SG Americas Securities LLC lessened its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 61.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,432 shares of the company's stock after selling 13,633 shares during the period.
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026 Well-capitalized with $1.6 billion 1 in cash and runway into 2029 Kymera to present its 2026 objectives at the J.P. Morgan 44 th Annual Healthcare Conference today at 9:00 a.m.
Kymera Therapeutics (KYMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $78.06, for a total value of $2,341,800.00. Following the completion of the transaction, the chief executive officer directly owned 663,077 shares
Insider buying can be one of the cleanest “follow-the-money” signals in the market. Over the past month or so, three names have stood out for $100 million-plus buying tied to prominent funds and well-known professional investors.
In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.
Stock News iRobot enters Chapter 11: iRobot (IRBT) filed for Chapter 11 and agreed to be acquired by contract manufacturer Picea Robotics, saying operations and
China Universal Asset Management Co. Ltd. lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 77.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,079 shares of the company's stock after acquiring an additional 10,052 shares
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
Frontier Capital Management Co. LLC grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 272.7% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 491,810 shares of the company's stock after buying an additional 359,847 shares during the
WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the closing of its upsized underwritten public offering of $602.0 million of shares of its common stock. Kymera sold and issued 8,050,000 shares of its common stock, which includes 1,050,000 shares sold and issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock. The shares of common stock were sold at a public offering price of $86.00 per share. The gross proceeds to Kymera from the offering were approximately $692.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera.
WATERTOWN, Mass. , Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $602.
Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.
WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares of common stock to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Kymera Therapeutics (KYMR) shares surged over 40% to an all-time high Monday afternooon after the drugmaker reported positive results from an early test of an oral anti-inflammatory drug.
Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript